Peptide clinics require specialized payment processing because standard processors like Stripe classify all peptide sales as restricted pharmaceuticals. To secure stable processing, clinics must partner with a high-risk processor that uses manual underwriting to distinguish between compliant Category 1 compounding and prohibited Category 2 substances, avoiding algorithmic account terminations.
One of the most powerful tools available to peptide clinics seeking long-term account stability is direct BIN ownership. Learn more about what a BIN is and why owning one matters for high-risk merchants.
Why Standard Processors Reject Peptide Clinics
Standard processors operate on an aggregator model that relies on automated keyword scanning, making them incapable of evaluating the complex regulatory compliance of a modern peptide clinic.
Founders of peptide clinics, telehealth platforms, and compounding pharmacies often begin their operations using familiar payment gateways like Stripe, Square, or PayPal. These platforms offer frictionless onboarding, allowing a new clinic to accept payments within minutes. However, this ease of entry masks a fundamental structural incompatibility with the health and wellness industry.
The Aggregator Model vs. Regulated Industries
Standard processors function as payment aggregators. They pool thousands of merchants under a single master merchant account. To protect this master account from liability and card network fines, they employ aggressive automated monitoring systems. These algorithms scan websites, product descriptions, and transaction data for flagged keywords.
When an algorithm detects the word "peptide," it does not pause to evaluate whether the clinic is operating a fully compliant 503A compounding pharmacy dispensing Category 1 substances under physician prescription. It simply identifies a match against its restricted businesses list and initiates an account freeze.
The Risk of Frozen Funds
The consequence of this algorithmic approach is severe operational disruption. When a standard processor terminates an a[4]ccount, they typically freeze all incoming processing immediately. Furthermore, they often place a hold on existing funds for 90 to 180 days to mitigate potential chargeback risk. For a growing peptide clinic, losing access to working capital for six months is an existential threat.
"When an algorithm detects the word peptide, it does not pause to evaluate compliance. It simply flags and freezes."
The FDA Regulatory Landscape for Peptides
The FDA strictly regulates peptides through its compounding categories, and payment processors require merchants to adhere to these classifications to maintain their accounts.
To understand why payment processing is so difficult to secure, one must understand the current regulatory environment. The FDA regulates bulk drug substances used in compounding under sections 503A and 503B of the Food, Drug, and Cosmetic Act.[1] The agency's recent actions have significantly narrowed the scope of what can be legally compounded and sold.
Category 1 vs. Category 2 Peptides
The FDA places bulk drug substances into specific categories. Category 1 substances are those currently under evaluation that can generally be compounded by licensed pharmacies. Category 2 substances are those the FDA has identified as presenting sig[2]nificant safety risks, meaning they should not be compounded.
In late 2023 and early 2024, the FDA moved several highly popular peptides including AOD-9604, CJC-1295, Ipamorelin, and Thymosin alpha-1 from Category 1 to Category 2. This reclassification effectively banned compounding pharmacies from producing them. Payment processors are acutely aware of this list. Processing payments for Category 2 substances exposes the processor to immense regulatory liability and card network fines.
Scroll right to see full table
| Peptide | FDA Category | Legal to Compound? | Processor Risk |
|---|---|---|---|
| BPC-157 | Category 1 | Yes (under review) | Low |
| Semaglutide | Category 1 | Yes (shortage status) | Moderate |
| CJC-1295 | Category 2 | No | High |
| Ipamorelin | Category 2 | No | High |
| AOD-9604 | Category 2 | No | High |
The "Research Use Only" Gray Area
In response to these restrictions, a parallel market has emerged where vendors sell peptides labeled "For Research Use Only" and "Not for Human Consumption." While this labeling attempts to circumvent FDA compounding rules, the agency looks at the totality of the vendor's marketing. If a website's imagery, customer base, or implied messaging suggests human use, the FDA considers it misbranding and the sale of unapproved new drugs. Standard processors view the "Research Use Only" model as an unacceptable risk and will terminate these accounts upon discovery.
What to Look for in a Peptide Merchant Account
Securing stable processing requires partnering with a specialized high-risk processor that owns its Bank Identification Number and employs underwriters who understand FDA compounding regulations.
When standard aggregators fail, peptide clinics must transition to a dedicated high-risk merchant account. However, the high-risk processing market is fragmented, and not all providers offer the infrastructure required for long-term stability.
Direct Bank Relationships (BIN Ownership)
The most critical factor in choosing a processor is determining whether they own their Bank Identification Number. Processors that own their BIN control the underwriting process directly. They do not rely on a third-party sponsor bank's rigid, automated rules. This direct control is what allows a processor to evaluate a peptide clinic based on its actual compliance posture rather than relying on blanket keyword bans.
Manual Underwriting by Industry Experts
A specialized processor will assign a human underwriter to review your business. This underwriter must understand the difference between a Category 1 and Category 2 peptide. They must understand the operational difference between a licensed 503A pharmacy and an unregulated vendor. This manual review process takes longer than aggregator onboarding, but it ensures that once your account is approved, it is built on a foundation of mutual understanding, drastically reducing the risk of sudden termination.
Transparent Reserve Policies
High-risk processing often involves reserve requirements to manage chargeback exposure. A reputable processor will clearly define these terms upfront. They will explain whether they require a rolling reserve, the percentage held, and the release schedule, allowing the clinic to manage its cash flow predictably.
How DIVIOR Supports Peptide Clinics
We provide institutional-grade payment infrastructure with direct BIN ownership, allowing our manual underwriting team to support compliant peptide clinics with unparalleled stability.
At DIVIOR, we built our infrastructure to serve the complex needs of the health and wellness industry. We understand that the global peptide therapeutics market is expanding rapidly, and compliant clinics require payment infrastructure that scales with them, not against them.
Because we own our Bank Identification Number, we control our underwriting decisions. Our team understands the nuances of FDA compounding regulations. We know how to evaluate a clinic dispensing Category 1 peptides under proper medical supervision. We do not rely on automated algorithms that penalize compliant businesses for operating in a regulated space.
As a USA-based and FSP-registered institution, we provide the direct bank relationships necessary for long-term operational stability. We evaluate your business on its actual merits, ensuring your payment processing is as reliable as your clinical protocols.
"We evaluate your business on its actual merits. Not an algorithm. Not a keyword list. A human underwriter who understands your industry."